Skip to the beginning of the images gallery

Innovation through M&A: Promega's Taxable Acquisition of Ophidian

Reference: DARDEN-C-2432-E
Number of pages: 6
Publication Date: Dec 17, 2020
Fecha de edición: Feb 7, 2022
Source: Darden University of Virginia (USA)
Type of Document: Case

Grouped product items
Format	Language	Reference	Use	Qty	Price	Preview
pdf	English	DARDEN-C-2432-E			As low as €8.20	Preview

You already have a subscription

To order please contact the person in charge of academic purchases in your university.

You'll be able to order once your profile has been validated.

Description

The tax director for Promega Corporation (Promega), was finalizing a deal to buy Ophidian Pharmaceuticals, Inc. (Ophidian), and needed to settle on a deal structure. Given that the consideration paid for Ophidian was going to be primarily cash, the deal would be taxable. The question for her to address was: Should Promega buy the assets or stock of Ophidian? She had to consider the after-tax consequences to Promega and Ophidian from the different deal structures, in order to figure out the optimal deal structure and be well prepared to negotiate. Promega’s chairman and CEO was ready to make the deal happen and a board meeting was on the schedule to discuss the specifics.

Keywords

merger